Development of high drug-loading nanomicelles targeting steroids to the brain

International Journal of Nanomedicine

Volumn 9, Issue 1, 2013, Pages 55-66

  Zheng, Sijia ^a   Xie, Yanqi ^a   Li, Yuan ^a   Li, Ling ^a   Tian, Ning ^a   Zhu, Wenbo ^b   Yan, Guangmei ^b   Wu, Chuanbin ^a   Hu, Haiyan ^a  

^a Institute of Clinical Pharmacology   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Brain targeting; Cholesterol; Drug loading; Lactoferrin; Nanomicelles; Sodium alginate

Indexed keywords

ALGINIC ACID; CHOLESTEROL; LACTOFERRIN SODIUM ALGINATE CHOLESTEROL DERIVATIVE NANOMICELLE; LIFICIGUAT; NANOCARRIER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN; CONTROLLED STUDY; CRITICAL MICELLE CONCENTRATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG RELEASE; DRUG RETENTION; DRUG SOLUBILITY; DRUG TARGETING; EMULSION; ENDOCYTOSIS; ESTERIFICATION; FEMALE; IMMUNOELECTRON MICROSCOPY; MALE; MEAN RESIDENCE TIME; MORPHOLOGY; MOUSE; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; SUSTAINED DRUG RELEASE; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL;

BRAIN-TARGETING; CHOLESTEROL; DRUG-LOADING; LACTOFERRIN; NANOMICELLES; SODIUM ALGINATE;

ANIMALS; BRAIN; CHOLESTANOLS; DIFFUSION; FEMALE; LACTOFERRIN; MALE; METABOLIC CLEARANCE RATE; MICE; MICELLES; NANOCAPSULES; ORGAN SPECIFICITY; PARTICLE SIZE; TISSUE DISTRIBUTION;

EID: 84890530815     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S52576     Document Type: Article

References (36)

1. Xu S-B, Wang Z-L, Liu Q, Li R-S. Anti-infammation actions of soft coral cholestane. Tropic Oceanology. 1999(2):27-32.
2. Guangmei Yan JZ, et al; Inventors. Application of oceanic steroidal compounds in preparing neuron lesion theraputic agents. China patent CN200610036926.
3. Branco MC, Schneider J P. Self-assembling materials for therapeutic delivery. Acta Biomater. 2009;5(3):817-831.
4. Be Duneau A, Saulnier P, Benoit J P. Active targeting of brain tumors using nanocarriers. Biomaterials. 2007;28(33):4947-4967.
5. Schmid R. Recent advances in the description of the structure of water, the hydrophobic effect, and the like-dissolves-like rule. Highlights in Solute-Solvent Interactions. Berlin: Springer; 2002: 59-90.
6. Robitzer M, David L, Rochas C, Renzo FD, Quignard F. Nanostructure of calcium alginate aerogels obtained from multistep solvent exchange route. Langmuir. 2008;24(21):12547-12552.
7. Yang L, Zhang B, Wen L, Liang Q, Zhang LM. Amphiphilic cholesteryl grafted sodium alginate derivative: Synthesis and self-assembly in aqueous solution. Carbohydr Polym. 2007;68(2):218-225.
8. Ying X, Wen H, Lu W-L, et al. Dual-targeting daunorubicin liposomes improve the therapeutic effcacy of brain glioma in animals. J Control Release. 2010;141(2):183-192.
9. Pardridge WM. Crossing the blood-brain barrier: are we getting it right? Drug Discov Today. 2001;6(1):1-2.
10. Patel MM, Goyal BR, Bhadada S V, Bhatt JS, Amin A F. Getting into the brain: approaches to enhance brain drug delivery. CNS Drugs. 2009;23(1):35-58.
11. Visser CC, Voorwinden LH, Crommelin DJ, Danhof M, de Boer AG. Characterization and modulation of the transferrin receptor on brain capillary endothelial cells. Pharm Res. 2004;21(5):761-769.
12. Bickel U, Yoshikawa T, Pardridge WM. Delivery of peptides and proteins through the blood-brain barrier. Adv Drug Deliv Rev. 2001; 46(1-3):247-279.
13. Pardridge WM, Eisenberg J, Yang J. Human blood-brain barrier trans-ferrin receptor. Metabolism. 1987;36(9):892-895.
14. Jefferies WA, Brandon MR, Hunt S V, Williams AF, Gatter KC, Mason DY. Transferrin receptor on endothelium of brain capillaries. Nature. 1984;312(5990):162-163.
15. Letchford K, Burt H. A review of the formation and classification of amphiphilic block copolymer nanoparticulate structures: micelles, nanospheres, nanocapsules and polymersomes. Eur J Pharm Biopharm. 2007;65(3):259-269.
16. Baker EN, Baker HM, Kidd RD. Lactoferrin and transferrin: functional variations on a common structural framework. Biochem Cell Biol. 2002;80(1):27-34.
17. Huang R, Ke W, Liu Y, Jiang C, Pei Y. The use of lactoferrin as a ligand for targeting the polyamidoamine-based gene delivery system to the brain. Biomaterials. 2008;29(2):238-246.
18. Talukder MJ, Takeuchi T, Harada E. Receptor-mediated transport of lactoferrin into the cerebrospinal fuid via plasma in young calves. J Ve t Med Sci. 2003;65(9):957-964.
19. Fillebeen C, Descamps L, Dehouck M P, et al. Receptor-mediated transcytosis of lactoferrin through the blood-brain barrier. J Biol Chem. 1999;274(11):7011-7017.
20. Elfnger M, Maucksch C, Rudolph C. Characterization of lactoferrin as a targeting ligand for nonviral gene delivery to airway epithelial cells. Biomaterials. 2007;28(23):3448-3455.
21. Grau AJ, Willig V, Fogel W, Werle E. Assessment of plasma lactoferrin in Parkinson's disease. Mov Disord. 2001;16:131-134.
22. Terent A, Hallgren R, Venge P, Bergstrom K. Lactoferrin, lysozyme, and beta 2-microglobulin in cerebrospinal fuid. Elevated levels in patients with acute cerebrovascular lesions as indices of infammation. Stroke. 1981;12(1):40-46.
23. Cipolla MJ, Crete R, Vitullo L, Rix RD. Transcellular transport as a mechanism of blood-brain barrier disruption during stroke. Front Biosci. 2004;9:777-785.
24. Chen Y, Liu L. Modern methods for delivery of drugs across the blood-brain barrier. Adv Drug Deliv Rev. 2012;64(7):640-665.
25. Heggelund A, Undheim K. Descladinosyl erythromycin in phosgene-assisted cyclic 3,6-ether formation. Tetrahedron Lett. 2008;49(39): 5569-5571.
26. Liu L, Guo K, Lu J, et al. Biologically active core/shell nanoparticles self-assembled from cholesterol-terminated PEG-TAT for drug delivery across the blood-brain barrier. Biomaterials. 2008;29(10):1509-1517.
27. Hu KL, Li J W, Shen YH, et al. Lactoferrin-conjugated PEG-PLA nano-particles with improved brain delivery: in vitro and in vivo evaluations. J Control Release. 2009;134:55-61.
28. Sethuraman VA, Bae YH. TAT peptide-based micelle system for potential active targeting of anti-cancer agents to acidic solid tumors. J Control Release. 2007;118(2):216-224.
29. Goddard ED, Turro NJ, Kuo PL, Ananthapadmanabhan K P. Fluorescence probes for critical micelle concentration determination. Langmuir. 1985;1(3):352-355.
30. Wang JX, Sun X, Zhang ZR. Enhanced brain targeting by synthesis of 3′,5′-dioctanoyl-5-fuoro-2′-deoxyuridine and incorporation into solid lipid nanoparticles. Eur J Pharm Biopharm. 2002;54(3): 285-290.
31. Goren Z, Heeg MJ, Mobashery S. Facile chloride substitution of activated alcohols by triphosgene: application to cephalosporin chemistry. J Org Chem. 1991;56(25):7186-7188.
32. Liu JB, Xiao YH, Allen C. Polymer-drug compatibility: a guide to the development of delivery systems for the anticancer agent, ellipticine. J Pharm Sci. 2004;93:132-143.
33. Vassiliou AA, Papadimitriou SA, Bikiaris DN, Mattheolabakis G, Avgoustakis K. Facile synthesis of polyester-PEG triblock copolymers and preparation of amphiphilic nanoparticles as drug carriers. J Control Release. 2010;148(3):388-395.
34. Wang J, del Rosario LS, Demirdirek B, Bae A, Uhrich KE. Comparison of PEG chain length and density on amphiphilic macromolecular nanocarriers: self-assembled and unimolecular micelles. Acta Biomater. 2009;5(3):883-892.
35. Memisoglu E, Bochot A, Sen M, Duchene D, Hincal AA. Non-surfactant nanospheres of progesterone inclusion complexes with amphiphilic beta-cyclodextrins. Int J Pharm. 2003;251(1-2):143-153.
36. Veiseh O, Gunn J W, Zhang M. Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging. Adv Drug Deliv Rev. 2010;62(3):284-304.